Lorlatinib Combinations in Lung Cancer

Clinical trial NCT04292119 · UNKNOWN

Trial details

NCT number: NCT04292119
Sponsor: Massachusetts General Hospital
Status: UNKNOWN
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Lung Cancer Anaplastic Lymphoma Kinase Gene Translocation ROS1 Rearrangement Relapsed Cancer MET Amplification Resistant Cancer NSCLC

Start date: 2020-05-01
Primary completion: 2022-12-01
Enrollment: 96

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.